Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Galapagos N.V.
DescriptionFree fatty acid receptor 2 (FFAR2; GPR43) antagonist
Molecular Target Free fatty acid receptor 2 (FFAR2) (GPR43)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationInflammatory bowel disease (IBD)
Indication DetailsTreat ulcerative colitis (UC)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today